Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 1/20 | 0.46 |
| ▸ | DRD2 | P14416 | 1/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18458736 | 0.85 | MEN1 (0.56) | KCNH2MEN1KMT2ASLC6A3HSD11B1 | |
| SCHEMBL21337310 | 0.81 | MEN1 (0.52) | KCNH2MEN1KMT2ASLC6A3HSD11B1 | |
| SCHEMBL18458294 | 0.80 | KCNA3 (0.58) | OPRM1 | |
| SCHEMBL18457935 | 0.78 | HTR1A (0.57) | KCNH2MEN1KMT2AHTR1ADRD2 | |
| SCHEMBL7264546 | 0.72 | SLC6A3 (0.83) | KCNH2MEN1KMT2ASLC6A3HTR1A | |
| SCHEMBL13150782 | 0.72 | SLC6A3 (0.83) | KCNH2MEN1KMT2ASLC6A3HTR1A | |
| SCHEMBL6056974 | 0.72 | SLC6A3 (0.83) | KCNH2MEN1KMT2ASLC6A3HTR1A | |
| SCHEMBL14407778 | 0.72 | SLC6A3 (0.83) | KCNH2MEN1KMT2ASLC6A3HTR1A | |
| SCHEMBL10902405 | 0.72 | MEN1 (0.67) | KCNH2MEN1KMT2ASLC6A3HTR1A | |
| SCHEMBL19281805 | 0.72 | SIGMAR1 (0.49) | KCNH2KMT2ADRD2SIGMAR1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10428051-B2 | Substituted amide derivatives having multimodal activity against pain | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-10-01 | — | — | US | disclosed |
| US-20190002443-A1 | SUBSTITUTED AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2019-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428051-B2 | Substituted amide derivatives having multimodal activity against pain | OPRM1, OPRD1, OPRK1 | KCNH2 1091/4885MEN1 4882/4885KMT2A 2699/4885 |
| US-20190002443-A1 | SUBSTITUTED AMIDE DERIVATIVES HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRM1, OPRD1, OPRK1 | KCNH2 1091/4885MEN1 4882/4885KMT2A 2699/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.